SBIR-STTR Award

Development of Serum Based Biomarker for the Detection of Cancer
Award last edited on: 3/25/2008

Sponsored Program
SBIR
Awarding Agency
DOD : OSD
Total Award Amount
$849,997
Award Phase
2
Solicitation Topic Code
OSD01-DHP02
Principal Investigator
Joe Lucas

Company Information

A L Tech Biomedical Inc

9700 Great Seneca Highway Suite 194
Rockville, MD 20850
   (703) 558-3400
   N/A
   N/A
Location: Single
Congr. District: 08
County: Montgomery

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2002
Phase I Amount
$99,998
We propose a breakthrough technique for ultra rapid, sensitive detection of cancer specific chromosome rearrangements in solution to facilitate bulk quantification of tumor cells for early detection of metastatic tumor cells in bone marrow, lymph nodes, and peripheral blood. Combining two separate, novel techniques (1) hybridization of chromosomes in suspension using (2) Repeat Sequence Depleted DNA probes, we will: (I) Apply DNA hybridization in suspension to human breast cancer cell lines. Chromosome aberrations will be detected using reversible DNA-hybridization probes that uniquely bind to DNA normally present in a specified subset of the genome. A second set of reversible DNA hybridization probes is used to uniquely hybridize with a corresponding second subset of the genome. Any (aberrant) chromosomes containing both subsets will be rapidly, efficiently isolated and quantified. (II) We will determine the translocation detection sensitivity using serial dilutions of a human breast cancer cell line (with known translocation) with the human lymphoblast cell line AG122. We expect our technique will have sensitivity similar to PCR and far higher than FISH, with specificity similar to or better than PCR and FISH, thus revolutionizing FISH and PCR medical diagnostics techniques. The research will lead to technology for licensing and commercial kits for early diagnoses of metastatic tumors as well as detecting minimal residual disorders in hematological malignancies. Pharmaceutical, biotech and hospitals will embrace this technology as it will lead to early detection of metastatic tumors cells and minimal residual leukemia cells. Early detection will increase patient survival, profoundly

Keywords:
Hybridization In Suspension, Metastatic Tumor, Translocations, Breast Cancer, Detection

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2002
Phase II Amount
$749,999
We propose an innovative technique for ultra rapid, sensitive detection of cancer specific chromosome rearrangements in solution to facilitate bulk quantification of aberrant chromosomes for early detection of metastatic tumor cells. (I) We will apply DNA hybridization in suspension to human breast cancer cell lines by combining two separate, novel techniques 1) hybridizing chromosomes in suspension; 2) using repeat sequence deplete DNA probes in combination with a flow cytometric method of analysis and magnetic sorting, in order to sensitively, precisely and rapidly quantify cancer-related chromosome translocations and rearrangements. Chromosome aberrations will be detected using reversible DNA-hybridization probes that uniquely bind to DNA normally present in a specific subset of the genome. A second set of reversible DNA hybridization probes will be used to uniquely hybridize with a corresponding second subset of the genome. Any (aberrant) chromosomes containing both subsets will be rapidly and efficiently isolated and quantified. (II) We will determine the translocation detection sensitivity (has a potential sensitivity of 1x1,000,000) using serial dilutions of a human breast cancer cell line with known translocation with the lymphoblast cell line AG122. We expect our technique will have sensitivity similar to PCR and far higher than FISH, with specificity better than PCR.

Keywords:
HYBRIDIZATION IN SUSPENSION, METASTATIC TUMOR CELLS, TRANSLOCATIONS, BREAST CANCER, DETECTION, RADIATION EXPOSURE